AI Terminal

MODULE: AI_ANALYST
Interactive Q&A, Risk Assessment, Summarization
MODULE: DATA_EXTRACT
Excel Export, XBRL Parsing, Table Digitization
MODULE: PEER_COMP
Sector Benchmarking, Sentiment Analysis
SYSTEM ACCESS LOCKED
Authenticate / Register Log In

SURGICAL INNOVATIONS GROUP PLC

Share Issue/Capital Change Jul 27, 2017

7938_rns_2017-07-27_db8a8760-29ea-47a0-8776-cb5034625172.html

Share Issue/Capital Change

Open in Viewer

Opens in native device viewer

National Storage Mechanism | Additional information

You don't have Javascript enabled. For full functionality this page requires javascript to be enabled.

RNS Number : 2873M

Surgical Innovations Group PLC

27 July 2017

THIS ANNOUNCEMENT AND THE INFORMATION CONTAINED HEREIN IS RESTRICTED AND IS NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN, INTO OR FROM THE UNITED STATES, AUSTRALIA, CANADA, JAPAN, THE REPUBLIC OF SOUTH AFRICA OR ANY OTHER JURISDICTION IN WHICH SUCH RELEASE, PUBLICATION OR DISTRIBUTION WOULD BE UNLAWFUL.

Surgical Innovations Group plc

Result of the Placing, Directors' Participation and Related Party Transaction

Further to the accelerated bookbuilding process and proposed Acquisition of Elemental Healthcare Limited announced earlier today, the Company is pleased to announce that the Vendor Placing and the Subscriptions have, in aggregate, conditionally raised gross proceeds of approximately £5.5 million through the issue of 183,333,333 New Ordinary Shares at a price of 3p per share.

Directors' Participation

Certain of the Directors have conditionally subscribed for New Ordinary Shares as follows:

Director Number of New Ordinary Shares subscribed for Holding of Ordinary Shares  following Admission % of Enlarged Issued Share Capital following Admission
Nigel Rogers 710,385 4,403,863 0.56
Melanie Ross 333,333 1,573,710 0.20
Paul Hardy 1,538,990 5,914,464 0.76
Mike McMahon 166,666 18,504,737 2.37

Related Party Transaction

Getz Bros. & Co. (BVI) Limited, which is a substantial shareholder in the Company as defined in the AIM Rules, has conditionally agreed to subscribe for 20,296,706 New Ordinary Shares (the "Getz Subscription").  The Getz Subscription constitutes a related party transaction for the purposes of the AIM Rules.  Alistair Taylor, the Director who has not conditionally subscribed for New Ordinary Shares, having consulted with WH Ireland, the Company's nominated adviser, considers that the terms of the Getz Subscription are fair and reasonable insofar as Shareholders are concerned.

Application has been made to the London Stock Exchange for admission to trading of the New Ordinary Shares on AIM.  It is expected that Admission will take place and dealings in the New Ordinary Shares will commence at 8.00 a.m. on 1 August 2017 at which time the Vendor Placing, the Subscriptions and the Acquisition will become unconditional.

The New Ordinary Shares will, when issued, be credited as fully paid and will rank pari passu in all respects with the Existing Ordinary Shares, including the right to receive all dividends or other distributions made, paid or declared in respect of such shares after Admission.

Following Admission and the issue of the New Ordinary Shares, there will be 780,264,588 Ordinary Shares in issue.

Capitalised terms used but not defined in this announcement shall have the meanings defined in the announcement issued earlier today.

This Announcement contains inside information for the purposes of Article 7 of EU Regulation 596/2014.

Contact details:

Surgical Innovations Group Plc www.sigroupplc.com
Nigel Rogers, Executive Chairman Tel: 0113 230 7597
Melanie Ross, COO & CFO
WH Ireland Limited (NOMAD & Broker) Tel: 020 7220 1666
Tim Feather (Corporate Finance)

David Kilbourn (Corporate Broking)
Walbrook PR (Financial PR & Investor Relations) Tel: 020 7933 8780 or [email protected]
Paul McManus Mob: 07980 541893
Lianne Cawthorne Mob: 07584 391303

This information is provided by RNS

The company news service from the London Stock Exchange

END

ROIOKODPCBKKDOB

Talk to a Data Expert

Have a question? We'll get back to you promptly.